

# John R Traynor

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3281246/publications.pdf>

Version: 2024-02-01

127  
papers

4,357  
citations

134610

34  
h-index

145109

60  
g-index

130  
all docs

130  
docs citations

130  
times ranked

4501  
citing authors

#	ARTICLE	IF	CITATIONS
1	In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs. <i>Scientific Reports</i> , 2022, 12, 5320.	1.6	15
2	SAR Matrices Enable Discovery of Mixed Efficacy $\mu$ -Opioid Receptor Agonist Peptidomimetics with Simplified Structures through an Aromatic-Amine Pharmacophore. <i>ACS Chemical Neuroscience</i> , 2021, 12, 216-233.	1.7	1
3	Positive allosteric modulation of the mu-opioid receptor produces analgesia with reduced side effects. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	36
4	A Virtual Docking Screen at 23 SARS-CoV-2 Proteins Identifies Drug Repurposing Candidates at New Sites and Targets. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
5	The Buprenorphine Analogue BU10119 Attenuates Drug-Primed and Stress-Induced Cocaine Reinstatement in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 378, 287-299.	1.3	8
6	Mice Expressing Regulators of G protein Signaling $\alpha$ Insensitive $G_{i\alpha}$ Define Roles of $\mu$ Opioid Receptor $G_{i\alpha}$ and $G_{i\beta}$ Subunit Coupling in Inhibition of Presynaptic GABA Release. <i>Molecular Pharmacology</i> , 2021, 100, 217-223.	1.0	6
7	Reply to Zhuang et al.: Potential side effects of positive allosteric modulators of the mu-opioid receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2108493118.	3.3	0
8	Mixed-solvent molecular dynamics simulation-based discovery of a putative allosteric site on regulator of G protein signaling 4. <i>Journal of Computational Chemistry</i> , 2021, 42, 2170-2180.	1.5	5
9	Allosteric Modulator Leads Hiding in Plain Site: Developing Peptide and Peptidomimetics as GPCR Allosteric Modulators. <i>Frontiers in Chemistry</i> , 2021, 9, 671483.	1.8	7
10	In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis. <i>Drug Testing and Analysis</i> , 2020, 12, 1212-1221.	1.6	26
11	Pharmacological Properties of $\mu$ -Opioid Receptor-Mediated Behaviors: Agonist Efficacy and Receptor Reserve. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 374, 319-330.	1.3	13
12	The Intriguing Effects of Substituents in the N-Phenethyl Moiety of Norhydromorphone: A Bifunctional Opioid from a Set of Tail Wags Dog Experiments. <i>Molecules</i> , 2020, 25, 2640.	1.7	10
13	Regulator of G-Protein Signaling (RGS) Protein Modulation of Opioid Receptor Signaling as a Potential Target for Pain Management. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 5.	1.4	29
14	Aromatic-Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy $\mu$ -Opioid Receptor (MOR)/ $\delta$ -Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic Stability. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 1671-1683.	2.9	10
15	The $\mu$ -opioid receptor positive allosteric modulator BMS 986187 is a G-protein-biased allosteric agonist. <i>British Journal of Pharmacology</i> , 2019, 176, 1649-1663.	2.7	36
16	Novel Dimethyltyrosine-Tetrahydroisoquinoline Peptidomimetics with Aromatic Tetrahydroisoquinoline Substitutions Show In Vitro $\kappa$ and $\mu$ Opioid Receptor Agonism. <i>ACS Chemical Neuroscience</i> , 2019, 10, 3682-3689.	1.7	3
17	Dual Pharmacophores Explored via Structure-Activity Relationship (SAR) Matrix: Insights into Potent, Bifunctional Opioid Ligand Design. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4193-4203.	2.9	8
18	Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic $\mu$ -Opioid Receptor (MOR) Agonist/ $\delta$ -Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4142-4157.	2.9	8

#	ARTICLE	IF	CITATIONS
19	Structure-Activity Relationships of 7-Substituted Dimethyltyrosine-Tetrahydroisoquinoline Opioid Peptidomimetics. <i>Molecules</i> , 2019, 24, 4302.	1.7	3
20	Buprenorphine C7-Esters with Improved Nociceptin Receptor Agonist Potency as Analgesics. <i>FASEB Journal</i> , 2019, 33, 663.16.	0.2	0
21	Loss of RGS Control at $G_{i/o}$ Reveals a Balance Between Nociceptin and $\mu$ -Opioid Receptor Systems. <i>FASEB Journal</i> , 2019, 33, 669.12.	0.2	0
22	A Docking-Based Virtual Screen for Bifunctional $\mu$ -Opioid Agonist/ $\delta$ -Opioid Antagonist Compounds. <i>FASEB Journal</i> , 2019, 33, 670.4.	0.2	0
23	Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity $\mu/\delta$ Opioid Ligands for the Treatment of Pain. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1840-1848.	1.7	15
24	<i>In vivo</i> effects of $\mu$ -opioid receptor agonist/ $\delta$ -opioid receptor antagonist peptidomimetics following acute and repeated administration. <i>British Journal of Pharmacology</i> , 2018, 175, 2013-2027.	2.7	31
25	Role of signalling molecules in behaviours mediated by the $\delta$ opioid receptor agonist SNC80. <i>British Journal of Pharmacology</i> , 2018, 175, 891-901.	2.7	31
26	Allostery at opioid receptors: modulation with small molecule ligands. <i>British Journal of Pharmacology</i> , 2018, 175, 2846-2856.	2.7	59
27	Pharmacologic Evidence for a Putative Conserved Allosteric Site on Opioid Receptors. <i>Molecular Pharmacology</i> , 2018, 93, 157-167.	1.0	35
28	Role of the guanine nucleotide binding protein, $G_{i/o}$ , in the development of morphine tolerance and dependence. <i>Psychopharmacology</i> , 2018, 235, 71-82.	1.5	6
29	The Role of G-proteins and G-protein Regulating Proteins in Depressive Disorders. <i>Frontiers in Pharmacology</i> , 2018, 9, 1289.	1.6	27
30	Role of hippocampal 5-HT <sub>1A</sub> receptors in the antidepressant-like phenotype of mice expressing RGS-insensitive $G_{i2}$ protein. <i>Neuropharmacology</i> , 2018, 141, 296-304.	2.0	2
31	Regulators of G-Protein Signaling (RGS) Proteins Promote Receptor Coupling to G-Protein-Coupled Inwardly Rectifying Potassium (GIRK) Channels. <i>Journal of Neuroscience</i> , 2018, 38, 8737-8744.	1.7	24
32	Measuring ligand efficacy at the $\mu$ -opioid receptor using a conformational biosensor. <i>ELife</i> , 2018, 7, .	2.8	40
33	RGS Protein Regulation of CB <sub>1</sub> Receptor-Mediated Cannabinoid Behaviors. <i>FASEB Journal</i> , 2018, 32, 825.4.	0.2	0
34	Analysis of Antinociception Produced by Positive Allosteric Modulators of the $\mu$ -Opioid Receptor. <i>FASEB Journal</i> , 2018, 32, 684.6.	0.2	0
35	A Novel Approach to Safer Analgesics: $\mu$ Opioid Receptor Agonist & $\delta$ Opioid Receptor Antagonist Peptidomimetics. <i>FASEB Journal</i> , 2018, 32, 689.6.	0.2	0
36	Modulation of opioid receptor affinity and efficacy via N-substitution of 9 $\beta$ -hydroxy-5-(3-hydroxyphenyl)morphan: Synthesis and computer simulation study. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 2406-2422.	1.4	9

#	ARTICLE	IF	CITATIONS
37	Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 666-669.	1.0	17
38	Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2549-2557.	1.7	9
39	The role of regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors. <i>Psychopharmacology</i> , 2017, 234, 29-39.	1.5	19
40	Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy $\mu$ -Opioid Receptor (MOR)/ $\delta$ -Opioid Receptor (DOR) Ligands. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4985-4998.	2.9	31
41	Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy $\mu$ -Opioid Receptor (MOR) Agonists/ $\delta$ -Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 8952-8969.	2.9	35
42	Structural insights into $\mu$ -opioid receptor activation. <i>Nature</i> , 2015, 524, 315-321.	13.7	743
43	Discovery, Synthesis, and Molecular Pharmacology of Selective Positive Allosteric Modulators of the $\delta$ -Opioid Receptor. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4220-4229.	2.9	54
44	C7-Methyl Analogues of the Orvinols: The Discovery of Kappa Opioid Antagonists with Nociceptin/Orphanin FQ Peptide (NOP) Receptor Partial Agonism and Low, or Zero, Efficacy at Mu Opioid Receptors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4242-4249.	2.9	23
45	Selectivity and Anti-Parkinson's Potential of Thiadiazolidinone RGS4 Inhibitors. <i>ACS Chemical Neuroscience</i> , 2015, 6, 911-919.	1.7	41
46	Rapid Synthesis of Boc- $\epsilon$ , $\epsilon$ -dimethyl-L-tyrosine and Derivatives and Incorporation into Opioid Peptidomimetics. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 1199-1203.	1.3	18
47	Challenges for opioid receptor nomenclature: IUPHAR Review 9. <i>British Journal of Pharmacology</i> , 2015, 172, 317-323.	2.7	115
48	Asymmetric Synthesis and in Vitro and in Vivo Activity of Tetrahydroquinolines Featuring a Diverse Set of Polar Substitutions at the 6 Position as Mixed-Efficacy $\mu$ -Opioid Receptor/ $\delta$ -Opioid Receptor Ligands. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1428-1435.	1.7	26
49	Ligand-Based Discovery of a New Scaffold for Allosteric Modulation of the $\mu$ -Opioid Receptor. <i>Journal of Chemical Information and Modeling</i> , 2015, 55, 1836-1843.	2.5	37
50	Nucleus accumbens shell excitability is decreased by methamphetamine self-administration and increased by 5-HT <sub>2C</sub> receptor inverse agonism and agonism. <i>Neuropharmacology</i> , 2015, 89, 113-121.	2.0	24
51	RGS4 Differentially Regulates Antidepressant and Locomotor Behaviors In Vivo. <i>FASEB Journal</i> , 2015, 29, 618.11.	0.2	0
52	Disruption of the Na <sup>+</sup> ion binding site as a mechanism for positive allosteric modulation of the mu-opioid receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 18369-18374.	3.3	51
53	5-HT <sub>1A</sub> receptor-mediated phosphorylation of extracellular signal-regulated kinases (ERK1/2) is modulated by regulator of G protein signaling protein 19. <i>Cellular Signalling</i> , 2014, 26, 1846-1852.	1.7	12
54	Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity $\mu$ -opioid receptor (MOR) agonist/ $\delta$ -opioid receptor (DOR) antagonist ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 548-551.	1.0	18

#	ARTICLE	IF	CITATIONS
55	Synergistic activity between the delta-opioid agonist SNC80 and amphetamine occurs via a glutamatergic NMDA-receptor dependent mechanism. <i>Neuropharmacology</i> , 2014, 77, 19-27.	2.0	12
56	Opioid Receptor Interacting Proteins and the Control of Opioid Signaling. <i>Current Pharmaceutical Design</i> , 2014, 19, 7333-7347.	0.9	26
57	Discovery of positive allosteric modulators and silent allosteric modulators of the $\delta$ -opioid receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 10830-10835.	3.3	123
58	Differential Control of Opioid Antinociception to Thermal Stimuli in a Knock-In Mouse Expressing Regulator of G-Protein Signaling-Insensitive $G_{i/o}$ Protein. <i>Journal of Neuroscience</i> , 2013, 33, 4369-4377.	1.7	29
59	Opioid Peptidomimetics: Leads for the Design of Bioavailable Mixed Efficacy $\delta$ Opioid Receptor (MOR) Agonist/ $\delta$ Opioid Receptor (DOR) Antagonist Ligands. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2139-2149.	2.9	45
60	Modulation of $\delta$ -Opioid Receptor Signaling by RGS19 in SH-SY5Y Cells. <i>Molecular Pharmacology</i> , 2013, 83, 512-520.	1.0	31
61	Modulation of Opioid Receptor Ligand Affinity and Efficacy Using Active and Inactive State Receptor Models. <i>Chemical Biology and Drug Design</i> , 2012, 80, 763-770.	1.5	22
62	$\delta$ -Opioid receptors and regulators of G protein signaling (RGS) proteins: From a symposium on new concepts in mu-opioid pharmacology. <i>Drug and Alcohol Dependence</i> , 2012, 121, 173-180.	1.6	69
63	Development and <i>in Vitro</i> Characterization of a Novel Bifunctional $\delta$ -Agonist/ $\delta$ -Antagonist Opioid Tetrapeptide. <i>ACS Chemical Biology</i> , 2011, 6, 1375-1381.	1.6	33
64	Regulators of G Protein Signaling (RGS) Proteins as Drug Targets: Modulating G-Protein-Coupled Receptor (GPCR) Signal Transduction. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 7433-7440.	2.9	40
65	Role of gonadal hormones on mu-opioid-stimulated [ $^{35}$ S]GTP $\gamma$ S binding and morphine-mediated antinociception in male and female Sprague-Dawley rats. <i>Psychopharmacology</i> , 2011, 218, 483-492.	1.5	8
66	Mu-Opioid Receptor Coupling to $G_{i/o}$ Plays an Important Role in Opioid Antinociception. <i>Neuropsychopharmacology</i> , 2011, 36, 2041-2053.	2.8	38
67	G $\alpha$ -Coupled Receptors Compete for Signaling to Adenylyl Cyclase in SH-SY5Y Cells and Reduce Opioid-Mediated cAMP Overshoot. <i>Molecular Pharmacology</i> , 2011, 79, 461-471.	1.0	35
68	Opioid-induced Down-Regulation of RGS4. <i>Journal of Biological Chemistry</i> , 2011, 286, 7854-7864.	1.6	27
69	Differential modulation of mu-opioid receptor signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in permeabilised C6 cells is $G_{i/o}$ subtype dependent. <i>Journal of Neurochemistry</i> , 2010, 112, 1026-1034.	2.1	29
70	Regulator of G protein signaling proteins and addictive drugs. <i>Annals of the New York Academy of Sciences</i> , 2010, 1187, 341-352.	1.8	31
71	RGS inhibition at $G_{i2}$ selectively potentiates 5-HT $_{1A}$ -mediated antidepressant effects. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 11086-11091.	3.3	60
72	Constitutively Active $\delta$ -Opioid Receptors. <i>Methods in Enzymology</i> , 2010, 484, 445-469.	0.4	19

#	ARTICLE	IF	CITATIONS
73	Competition between Gi/o-coupled receptors prevents cAMP overshoot following chronic opioid treatment. <i>FASEB Journal</i> , 2010, 24, 583.7.	0.2	0
74	The role of G $\beta$ o in mu-opioid signaling and antinociception. <i>FASEB Journal</i> , 2010, 24, 583.5.	0.2	0
75	Differential Modulation of $\delta$ - and $\mu$ -Opioid Receptor Agonists by Endogenous RGS4 Protein in SH-SY5Y Cells. <i>Journal of Biological Chemistry</i> , 2009, 284, 18357-18367.	1.6	48
76	Differential Effect of Membrane Cholesterol Removal on $\delta$ - and $\mu$ -Opioid Receptors. <i>Journal of Biological Chemistry</i> , 2009, 284, 22108-22122.	1.6	58
77	Role of protein kinase C in functional selectivity for desensitization at the $\mu$ -opioid receptor: from pharmacological curiosity to therapeutic potential. <i>British Journal of Pharmacology</i> , 2009, 158, 154-156.	2.7	16
78	G Protein independent phosphorylation and internalization of the $\delta$ -opioid receptor. <i>Journal of Neurochemistry</i> , 2009, 109, 1526-1535.	2.1	36
79	Pentapeptides Displaying $\delta$ Opioid Receptor Agonist and $\mu$ Opioid Receptor Partial Agonist/Antagonist Properties. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 7724-7731.	2.9	36
80	RGS9-2: probing an intracellular modulator of behavior as a drug target. <i>Trends in Pharmacological Sciences</i> , 2009, 30, 105-111.	4.0	38
81	Membrane cholesterol removal promotes a low agonist affinity state of mu opioid receptors. <i>FASEB Journal</i> , 2009, 23, 943.2.	0.2	0
82	Understanding ligand affinity and efficacy at mu and delta opioid receptors using cyclic pentapeptides. <i>FASEB Journal</i> , 2009, 23, 756.16.	0.2	0
83	Collision coupling, crosstalk, and compartmentalization in G-protein coupled receptor systems: Can a single model explain disparate results?. <i>Journal of Theoretical Biology</i> , 2008, 255, 278-286.	0.8	12
84	Comparison of the opioid receptor antagonist properties of naltrexone and 6 $\beta$ -naltrexol in morphine-naïve and morphine-dependent mice. <i>European Journal of Pharmacology</i> , 2008, 583, 48-55.	1.7	20
85	The selective delta opioid agonist SNC80 enhances amphetamine-mediated efflux of dopamine from rat striatum. <i>Neuropharmacology</i> , 2008, 55, 755-762.	2.0	19
86	Genetic deletion of Regulators of G protein Signaling (RGS) protein activity enhances buprenorphine antinociception while limiting withdrawal behaviors associated with chronic administration. <i>FASEB Journal</i> , 2008, 22, 907.7.	0.2	0
87	Mice lacking RGS protein activity at G $\beta$ i2 exhibit a 5HT1A receptor-mediated antidepressant-like phenotype. <i>FASEB Journal</i> , 2008, 22, 907.8.	0.2	0
88	Effects of membrane cholesterol modulation on mu opioid receptor signaling. <i>FASEB Journal</i> , 2008, 22, 727.5.	0.2	0
89	Effects of agonists with mixed efficacy profiles at the mu and kappa opioid receptor on amphetamine-mediated dopamine release. <i>FASEB Journal</i> , 2008, 22, 712.8.	0.2	0
90	Thienorphine: Receptor Binding and Behavioral Effects in Rhesus Monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 321, 227-236.	1.3	25

#	ARTICLE	IF	CITATIONS
91	Identification of Small-Molecule Inhibitors of RGS4 Using a High-Throughput Flow Cytometry Protein Interaction Assay. <i>Molecular Pharmacology</i> , 2007, 71, 169-175.	1.0	123
92	Isolation and Chemical Modification of Clerodane Diterpenoids from <i>Salvia</i> Species as Potential Agonists at the $\mu$ -Opioid Receptor. <i>Chemistry and Biodiversity</i> , 2007, 4, 1586-1593.	1.0	13
93	G Protein Independent Internalization of delta Opioid Receptors. <i>FASEB Journal</i> , 2007, 21, A426.	0.2	0
94	Disruption of lipid rafts enhances coupling of G-proteins to nonraft associated delta opioid receptors in HEK293 cells. <i>FASEB Journal</i> , 2007, 21, A430.	0.2	0
95	Biphasic regulation of $\mu$ -opioid signaling to adenylyl cyclase by GTPase accelerating protein (GAP) activity of RGS7. <i>FASEB Journal</i> , 2007, 21, A430.	0.2	0
96	Comparison of the in vitro efficacy of $\delta$ , $\kappa$ , $\mu$ and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes. <i>Brain Research</i> , 2006, 1073-1074, 290-296.	1.1	36
97	Differential in Vivo Potencies of Naltrexone and $\delta$ -Naltrexol in the Monkey. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 772-779.	1.3	42
98	Comparison of the Relative Efficacy and Potency of $\delta$ -Opioid Agonists to Activate $G_{i/o}$ Proteins Containing a Pertussis Toxin-Insensitive Mutation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 858-864.	1.3	47
99	Comparison of the Antinociceptive Response to Morphine and Morphine-Like Compounds in Male and Female Sprague-Dawley Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 1195-1201.	1.3	155
100	The selective delta opioid agonist SNC80 increases amphetamine-mediated release of dopamine. <i>FASEB Journal</i> , 2006, 20, A676.	0.2	0
101	Comparison of naltrexone and $\delta$ -naltrexol in morphine-naive and morphine-dependent mice. <i>FASEB Journal</i> , 2006, 20, A239.	0.2	0
102	BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism. <i>European Journal of Pharmacology</i> , 2005, 509, 117-125.	1.7	28
103	Comparison of the antinociceptive effect of acute morphine in female and male Sprague-Dawley rats using the long-lasting mu-antagonist methocinnamox. <i>Brain Research</i> , 2005, 1058, 137-147.	1.1	35
104	Comparison of Peptidic and Nonpeptidic $\delta$ -Opioid Agonists on Guanosine 5'-O-(3-[ <sup>35</sup> S]thio)triphosphate ([ <sup>35</sup> S]GTP $\gamma$ S) Binding in Brain Slices from Sprague-Dawley Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 1314-1320.	1.3	15
105	Endogenous Regulator of G Protein Signaling Proteins Reduce $\delta$ -Opioid Receptor Desensitization and Down-Regulation and Adenylyl Cyclase Tolerance in C6 Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 809-815.	1.3	19
106	Differential Behavioral Tolerance to the $\delta$ -Opioid Agonist SNC80 ((+)-4-[(1R)-1-[(2S,5R)-2,5-Dimethyl-4-(2-propenyl)-1-piperazinyl]-3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 315, 414-422.		42
107	REGULATORS OF G PROTEIN SIGNALING & DRUGS OF ABUSE. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2005, 5, 30-41.	3.4	86
108	Assays for G-Protein-Coupled Receptor Signaling Using RGS-Insensitive $G_{i/o}$ Subunits. <i>Methods in Enzymology</i> , 2004, 389, 155-169.	0.4	15

#	ARTICLE	IF	CITATIONS
109	Endogenous Regulator of G Protein Signaling Proteins Suppress $G_{i/o}$ -Dependent, $\mu$ -Opioid Agonist-Mediated Adenylyl Cyclase Supersensitization. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 310, 215-222.	1.3	37
110	Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting $\mu$ -opioid receptor agonist. <i>European Journal of Pharmacology</i> , 2004, 499, 107-116.	1.7	44
111	Endogenous RGS Protein Action Modulates $\mu$ -Opioid Signaling through $G_{i/o}$ . <i>Journal of Biological Chemistry</i> , 2003, 278, 9418-9425.	1.6	92
112	A Spatial Focusing Model for G Protein Signals. <i>Journal of Biological Chemistry</i> , 2003, 278, 7278-7284.	1.6	121
113	Delta Opioid Receptors and G Proteins. , 2003, , .		1
114	Comparison of Receptor Mechanisms and Efficacy Requirements for $\delta$ -Agonist-Induced Convulsive Activity and Antinociception in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 303, 723-729.	1.3	82
115	Relationship between Rate and Extent of G Protein Activation: Comparison between Full and Partial Opioid Agonists. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 157-161.	1.3	29
116	Nonpeptidic $\delta$ -opioid Receptor Agonists Reduce Immobility in the Forced Swim Assay in Rats. <i>Neuropsychopharmacology</i> , 2002, 26, 744-755.	2.8	171
117	Antinociceptive and other behavioral effects of the steroid SC17599 are mediated by the $\mu$ -opioid receptor. <i>European Journal of Pharmacology</i> , 2000, 395, 121-128.	1.7	11
118	Activation of G protein by opioid receptors: role of receptor number and G-protein concentration. <i>European Journal of Pharmacology</i> , 2000, 396, 67-75.	1.7	26
119	The Steroid 17 $\beta$ -Acetoxy-6-dimethylaminomethyl-21-fluoro-3-ethoxy-pregna-3,5-dien-20-one (SC17599) Is a Selective $\mu$ -Opioid Agonist: Implications for the $\mu$ -Opioid Pharmacophore. <i>Molecular Pharmacology</i> , 2000, 58, 669-676.	1.0	7
120	Synthesis and in Vitro and in Vivo Activity of ( $\delta^+$ )-(1R,5R,9R)- and (+)-(1S,5S,9S)-N-Alkenyl-, -N-Alkynyl-, and -N-Cyanoalkyl-5,9-dimethyl-2 $\beta$ -hydroxy-6,7-benzomorphan Homologues. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 5030-5036.	2.9	36
121	Constitutive activity of the $\delta$ -opioid receptor expressed in C6 glioma cells: identification of non-peptide $\delta$ -inverse agonists. <i>British Journal of Pharmacology</i> , 1999, 128, 556-562.	2.7	58
122	Differential binding properties of oripavines at cloned $\mu$ - and $\delta$ -opioid receptors. <i>European Journal of Pharmacology</i> , 1999, 378, 323-330.	1.7	97
123	3-Alkyl Ethers of Clocinnamox: $\Delta$ Delayed Long-Term $\mu$ -Antagonists with Variable $\mu$ Efficacy. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 3493-3498.	2.9	19
124	70 Cloning and characterization of a $\delta$ opioid receptor from zebrafish. <i>Biochemical Society Transactions</i> , 1998, 26, S360-S360.	1.6	18
125	Convulsive Behavior of Nonpeptide $\delta$ -Opioid Ligands: Comparison of SNC80 and BW373U86 in Mice. <i>Analgesia (Elmsford, N Y)</i> , 1998, 3, 269-276.	0.5	35
126	Tolerance to $\mu$ -opioid agonists in human neuroblastoma SH-SY5Y cells as determined by changes in guanosine-5 $\beta$ -O-(3-[ $^{35}$ S]-thio)triphosphate binding. <i>British Journal of Pharmacology</i> , 1997, 121, 1422-1428.	2.7	29



#	ARTICLE	IF	CITATIONS
127	Sodium ions increase the binding of the antagonist peptide ICI 174864 to the $\hat{\nu}$ -opiate receptor. <i>Neuropeptides</i> , 1986, 7, 139-143.	0.9	20